We use cookies to understand how you use our site and to improve your experience.
This includes personalizing content and advertising.
By pressing "Accept All" or closing out of this banner, you consent to the use of all cookies and similar technologies and the sharing of information they collect with third parties.
You can reject marketing cookies by pressing "Deny Optional," but we still use essential, performance, and functional cookies.
In addition, whether you "Accept All," Deny Optional," click the X or otherwise continue to use the site, you accept our Privacy Policy and Terms of Service, revised from time to time.
You are being directed to ZacksTrade, a division of LBMZ Securities and licensed broker-dealer. ZacksTrade and Zacks.com are separate companies. The web link between the two companies is not a solicitation or offer to invest in a particular security or type of security. ZacksTrade does not endorse or adopt any particular investment strategy, any analyst opinion/rating/report or any approach to evaluating individual securities.
If you wish to go to ZacksTrade, click OK. If you do not, click Cancel.
Abbott (ABT) Reports Q1 Earnings: What Key Metrics Have to Say
Read MoreHide Full Article
Abbott (ABT - Free Report) reported $9.75 billion in revenue for the quarter ended March 2023, representing a year-over-year decline of 18.1%. EPS of $1.03 for the same period compares to $1.73 a year ago.
The reported revenue compares to the Zacks Consensus Estimate of $9.64 billion, representing a surprise of +1.07%. The company delivered an EPS surprise of +5.10%, with the consensus EPS estimate being $0.98.
While investors scrutinize revenue and earnings changes year-over-year and how they compare with Wall Street expectations to determine their next move, some key metrics always offer a more accurate picture of a company's financial health.
Since these metrics play a crucial role in driving the top- and bottom-line numbers, comparing them with the year-ago numbers and what analysts estimated about them helps investors better project a stock's price performance.
Here is how Abbott performed in the just reported quarter in terms of the metrics most widely monitored and projected by Wall Street analysts:
Net sales- Diagnostics- U.S. $1.34 billion versus $1.44 billion estimated by four analysts on average. Compared to the year-ago quarter, this number represents a -51.3% change.
Net sales- Nutrition- International: $1.16 billion compared to the $1.13 billion average estimate based on four analysts. The reported number represents a change of -5.1% year over year.
Net sales- Nutrition- U.S. $812 million versus $738.46 million estimated by four analysts on average. Compared to the year-ago quarter, this number represents a +19.9% change.
Net sales- Diagnostics- International: $1.35 billion versus $1.58 billion estimated by four analysts on average. Compared to the year-ago quarter, this number represents a -46.8% change.
Net sales- Nutrition: $1.97 billion versus the five-analyst average estimate of $1.87 billion. The reported number represents a year-over-year change of +3.9%.
Net sales- Medical Devices- Diabetes Care: $1.31 billion compared to the $1.22 billion average estimate based on five analysts. The reported number represents a change of +16.6% year over year.
Net sales- Diagnostics: $2.69 billion compared to the $2.95 billion average estimate based on five analysts. The reported number represents a change of -49.2% year over year.
Net sales- Established Pharmaceuticals: $1.19 billion versus the five-analyst average estimate of $1.16 billion. The reported number represents a year-over-year change of +3.7%.
Net sales- Medical Devices- Vascular- Total: $617 million versus $609.10 million estimated by four analysts on average. Compared to the year-ago quarter, this number represents a -0.3% change.
Net sales- Medical Devices- Neuromodulation- Total: $196 million compared to the $180.72 million average estimate based on four analysts. The reported number represents a change of +9.5% year over year.
Net sales- Medical Devices- Structural Heart- Total: $461 million versus the four-analyst average estimate of $433.99 million.
Net sales- Medical Devices- Heart Failure- Total: $281 million compared to the $230.94 million average estimate based on four analysts. The reported number represents a change of +27.2% year over year.
Shares of Abbott have returned +5.9% over the past month versus the Zacks S&P 500 composite's +6.2% change. The stock currently has a Zacks Rank #3 (Hold), indicating that it could perform in line with the broader market in the near term.
See More Zacks Research for These Tickers
Normally $25 each - click below to receive one report FREE:
Image: Bigstock
Abbott (ABT) Reports Q1 Earnings: What Key Metrics Have to Say
Abbott (ABT - Free Report) reported $9.75 billion in revenue for the quarter ended March 2023, representing a year-over-year decline of 18.1%. EPS of $1.03 for the same period compares to $1.73 a year ago.
The reported revenue compares to the Zacks Consensus Estimate of $9.64 billion, representing a surprise of +1.07%. The company delivered an EPS surprise of +5.10%, with the consensus EPS estimate being $0.98.
While investors scrutinize revenue and earnings changes year-over-year and how they compare with Wall Street expectations to determine their next move, some key metrics always offer a more accurate picture of a company's financial health.
Since these metrics play a crucial role in driving the top- and bottom-line numbers, comparing them with the year-ago numbers and what analysts estimated about them helps investors better project a stock's price performance.
Here is how Abbott performed in the just reported quarter in terms of the metrics most widely monitored and projected by Wall Street analysts:
- Net sales- Diagnostics- U.S. $1.34 billion versus $1.44 billion estimated by four analysts on average. Compared to the year-ago quarter, this number represents a -51.3% change.
- Net sales- Nutrition- International: $1.16 billion compared to the $1.13 billion average estimate based on four analysts. The reported number represents a change of -5.1% year over year.
- Net sales- Nutrition- U.S. $812 million versus $738.46 million estimated by four analysts on average. Compared to the year-ago quarter, this number represents a +19.9% change.
- Net sales- Diagnostics- International: $1.35 billion versus $1.58 billion estimated by four analysts on average. Compared to the year-ago quarter, this number represents a -46.8% change.
- Net sales- Nutrition: $1.97 billion versus the five-analyst average estimate of $1.87 billion. The reported number represents a year-over-year change of +3.9%.
- Net sales- Medical Devices- Diabetes Care: $1.31 billion compared to the $1.22 billion average estimate based on five analysts. The reported number represents a change of +16.6% year over year.
- Net sales- Diagnostics: $2.69 billion compared to the $2.95 billion average estimate based on five analysts. The reported number represents a change of -49.2% year over year.
- Net sales- Established Pharmaceuticals: $1.19 billion versus the five-analyst average estimate of $1.16 billion. The reported number represents a year-over-year change of +3.7%.
- Net sales- Medical Devices- Vascular- Total: $617 million versus $609.10 million estimated by four analysts on average. Compared to the year-ago quarter, this number represents a -0.3% change.
- Net sales- Medical Devices- Neuromodulation- Total: $196 million compared to the $180.72 million average estimate based on four analysts. The reported number represents a change of +9.5% year over year.
- Net sales- Medical Devices- Structural Heart- Total: $461 million versus the four-analyst average estimate of $433.99 million.
- Net sales- Medical Devices- Heart Failure- Total: $281 million compared to the $230.94 million average estimate based on four analysts. The reported number represents a change of +27.2% year over year.
View all Key Company Metrics for Abbott here>>>Shares of Abbott have returned +5.9% over the past month versus the Zacks S&P 500 composite's +6.2% change. The stock currently has a Zacks Rank #3 (Hold), indicating that it could perform in line with the broader market in the near term.